Overview of Pulmofor retard

Quick Facts

Property	Description
Active ingredient	Dextromethorphan Hydrobromide
Form	Prolonged-release tablet (Retard tablet)
Pharmacological class	Antitussive Agent (Cough Suppressant)
Common use	Relief of unproductive and irritative cough
Origin	Synthetic compound, Non-opioid

What Type of Medicine is Pulmofor retard?

Pulmofor retard is a medication classified as a centrally acting antitussive agent, primarily intended to suppress the cough reflex. This single-ingredient product functions to provide targeted symptomatic relief from irritative cough or unproductive cough. The active substance functions to control the cough mechanism. Its pharmacological role firmly establishes it as a cough suppressant, distinguishing it from agents designed to facilitate mucus clearance. The general purpose of this classification is to provide targeted control over persistent, non-beneficial coughing, a common scenario during acute respiratory irritations.

Composition and Form: Dextromethorphan in a Prolonged-Release Tablet

The active ingredient in Pulmofor retard is Dextromethorphan Hydrobromide, a synthetic compound administered via an oral dosage form. It is specifically manufactured as a prolonged-release tablet, often termed a retard tablet, a formulation designed to ensure the steady, slow release of the active substance into the system. Dextromethorphan is structurally analogous to codeine but is categorized as a non-opioid compound relative to older antitussive compounds, meaning it achieves cough suppression without the classic analgesic effects. The substance belongs to the morphinan class and acts on the central nervous system. The retard tablet formulation, a key differentiating feature, utilizes a modified release system, offering the functional benefit of sustaining the cough-suppressant effect over an extended duration.

Core Function: How Does Pulmofor retard Help?

The general purpose of Pulmofor retard is to secure sustained relief by reducing the intensity and frequency of persistent coughing. It functions by acting upon the central cough center located in the medulla oblongata, where it influences the nerve signals to elevate the cough threshold. This central influence decreases the sensitivity of the entire cough reflex arc. The medication’s prolonged-release characteristic provides the practical advantage of a more reliable, long-lasting antitussive agent action, which is essential for managing irritating dry coughs that interfere with rest or daily activity.

Regulatory References

Dextromethorphan - StatPearls - NCBI Bookshelf

What side effects are possible with Pulmofor retard?

Possible Side Effects and Safety Information

The safety profile for Dextromethorphan Hydrobromide, the active ingredient in Pulmofor retard, is officially categorized in regulatory documents based on the systems and frequency of adverse reactions. Most adverse effects are associated with the Nervous System and Gastrointestinal System. In controlled clinical data, effects such as drowsiness and dizziness are often classified as uncommon side effects.

Official Safety Classifications and High-Level Risks

The official labeling organizes adverse reactions into System-Organ Classes (SOC) including Nervous System Disorders, Gastrointestinal Disorders (such as nausea and vomiting), and Immune System Disorders (hypersensitivity reactions).

Serious Adverse Reactions officially documented include the risk of Serotonin Syndrome when the medication is combined with certain serotonergic agents, most notably Monoamine Oxidase Inhibitors (MAOIs). Severe hypersensitivity reactions are also listed.

Population and Constraint Notes

The prescribing information establishes strict constraints, stating the medication is contraindicated for use in patients currently taking or within 14 days of discontinuing MAOI treatment. Caution is advised for specific populations, including those with hepatic impairment, as Dextromethorphan is metabolized by the liver. Furthermore, regulatory agencies acknowledge the potential for drug dependence associated with prolonged use of the active substance, even at therapeutic doses.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below outlines the officially documented clinical manifestations and required emergency actions for Dextromethorphan overdose, as defined by government regulatory authorities.

Overdose of the active substance may present with a range of central nervous system (CNS) effects. Documented manifestations include drowsiness, dizziness, ataxia (unsteady walking), agitation, confusion, and hallucinations. Physical signs can include mydriasis (dilated pupils), nystagmus (involuntary eye movement), and muscular effects such as rigidity or twitches. Gastrointestinal effects such as nausea and vomiting are also noted in official labeling.

Severe outcomes that constitute a life-threatening emergency are documented, including respiratory depression (slow or shallow breathing), seizures, and coma. Cardiovascular instability, such as tachycardia (fast heartbeat) and hypertension, is also a listed risk. A significant complication is the potential for Serotonin syndrome in patients who have taken concomitant serotonergic medicines.

Required Emergency Actions

Official regulatory guidance mandates that individuals must seek immediate medical attention following a suspected overdose. You must call emergency services immediately if the individual has collapsed, is experiencing trouble breathing or apnea, or can't be awakened. Immediate referral to an emergency department is required for any patient exhibiting severe effects or for cases involving intentional abuse or suicidal intent.

Overdose management is explicitly described as symptomatic and supportive treatment, with clinical procedures including monitoring of vital signs and the use of activated charcoal within one hour of ingestion.

Therapeutic Uses of Pulmofor retard

Pulmofor retard is commonly used for managing symptoms within the antitussive therapeutic domain, providing targeted symptomatic support in specific clinical contexts. The core focus is on minimizing the burden of symptoms related to physical discomfort caused by dry, irritative coughing, particularly when symptoms are persistent.

The medication is considered relevant for the symptomatic management of cough associated with acute episodes. This includes conditions such as the common cold, flu, or minor throat and bronchial irritations. The medication is applied in addressing these distressing manifestations, which may assist with easing the overall symptom burden.

“Pulmofor retard is primarily applied in scenarios where additional management of discomfort is required due to dry, persistent cough manifestations.”

Symptomatic Management for Episodes Interfering with Stability

The prolonged-release formulation is relevant in contexts involving heightened systemic burden where symptoms interfere with daily functioning and rest. Pulmofor retard offers symptomatic relief that is relevant for managing symptoms that endure over an extended period, which may assist with providing sustained symptomatic support. This supports the patient during difficult episodes by easing distress and maintaining a sense of stability when symptoms interfere with daily functioning and rest.

Quick Fact: Relief for Persistent Coughing
Primary Symptom Targeted	Irritative, unproductive dry cough
Primary Therapeutic Focus	Symptomatic management for symptoms that endure over time
Typical Context of Use	Acute episodes that disrupt rest or daily activity

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Pulmofor retard?

This section details the population eligibility and restrictions for Pulmofor retard (Dextromethorphan prolonged-release) based strictly on official regulatory labeling.

Contraindicated Populations

Use of this medicine is absolutely prohibited for:

Patients with a known hypersensitivity to Dextromethorphan or any component of the tablet.
Patients who are currently taking or have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days, due to the risk of severe drug interaction.
Individuals with chronic or persistent cough (e.g., due to smoking or asthma) or a cough associated with excessive secretions (productive cough).

Age and Physiological Restrictions

Population Group	Regulatory Status
Children under 12	Use of prolonged-release forms is generally not recommended or contraindicated.
Pregnancy	Safe use is not established; use is restricted to situations where the potential benefit justifies the potential risk.
Lactation	Not recommended due to excretion into breast milk.
Hepatic Impairment	Requires use with caution due to extensive metabolism by the liver.

Eligibility-Related Limitations

Official labeling advises that patients with severe renal impairment or those with a history of substance abuse should only use this medicine after seeking medical advice.

What should I know about interactions with other medicines?

The interaction profile for Dextromethorphan Hydrobromide is documented by regulatory authorities, focusing on metabolic effects and additive central nervous system risks.

Interaction Type	Interacting Substances/Substance Classes	Required Restriction
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs)	Prohibited; requires a 14-day separation period between use.
Pharmacokinetic	Strong CYP2D6 Inhibitors (e.g., Quinidine, Fluoxetine)	Co-administration may increase serum concentration and overall exposure.
Pharmacodynamic	Serotonergic Agents (e.g., SSRIs, SNRIs, Mirtazapine)	Increased risk of serotonin syndrome.
CNS Depressant	Alcohol and other Central Nervous System Depressants	Increases the CNS depressant effects.

The interaction profile establishes that co-administration with MAOIs is a formal contraindication. Strong inhibitors of the CYP2D6 enzyme, such as certain antidepressants and antiarrhythmics, are documented to affect the drug's metabolism, potentially leading to increased systemic exposure. The combination with other serotonergic medicines also raises the official risk of a serious additive effect. Furthermore, the profile notes that the use of alcohol must be avoided due to the documented increase in central depressant effects. For individuals identified as poor CYP2D6 metabolizers, exaggerated and prolonged effects are noted, which structurally mimics the effect of co-administering a strong inhibitor.

Mechanism of Action

How Pulmofor Retard Works: Mechanism and Physiological Effect

Central Signal Dampening: Targeting the Cough Reflex Center

The active substance, dextromethorphan, selectively targets the Central Nervous System (CNS), focusing its action on the medullary cough center in the brainstem. The molecule acts primarily as a non-competitive antagonist at N-methyl-D-aspartate (NMDA) receptors within this center. This molecular interaction initiates a mechanistic cascade that suppresses excitatory neural signals, thereby modulating the signal processing within the reflex pathway.

Raising the Threshold: The Physiological Consequence

This central mechanism modulates signaling patterns associated with heightened activity in the cough reflex pathway. By dampening the incoming input signals to the CNS, the molecule elevates the neural threshold required for the cough center to activate. This results in the suppression of signal transduction across the neuronal circuit, contributing to a change in the central processing of peripheral stimuli.

Sustained Delivery: Prolonging Mechanistic Activity

As a retard or sustained-release formulation, the drug is designed for a specific mechanistic activity pattern. This formulation ensures the consistent availability of the active molecule over an extended period, which maintains a uniform level of antagonism at the central receptors for the duration of the drug's effect.

Dosage and Administration Information

Administration and Usage Principles

Pulmofor retard is an antitussive medication containing Dextromethorphan Hydrobromide, designed as a prolonged-release tablet or capsule. The use of this medicine is governed by specific instructions to ensure the modified-release system functions correctly and to adhere to limits for acute symptom management.

Route and Integrity of the Dose

Administration is strictly by the oral route. The prolonged-release form must be swallowed whole with a small amount of liquid. It is a critical procedural requirement that the dose must not be crushed, chewed, or divided. Altering the form would destroy the mechanism that controls the slow, sustained release of the active substance.

Dosing Schedule and Duration

The standard regimen for the prolonged-release formulation requires twice-daily dosing, typically administered every 12 hours, to maintain a consistent antitussive effect over a full day. For example, a common regimen involves taking 60 mg every 12 hours, with a total maximum daily intake not to exceed 120 mg. The medicine may be taken without regard to the timing of meals.

Treatment with Dextromethorphan is intended for short-term use only. Guidance stipulates that the medication should be discontinued if the cough persists for more than seven days, reinforcing its role for the symptomatic management of acute episodes.

Administration Rules for Specific Populations

This prolonged-release formulation is not recommended for use in children under 12 years of age. If a dose is missed, patients are instructed to take it as soon as it is remembered unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped to avoid taking two doses simultaneously.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Summary: Scientific Focus

Research examined the effect of the investigational compound in studies focusing on enzyme inhibition. These studies explored potential effects on markers associated with inflammation.

Core Efficacy Studies (Phase III Trials)

Phase III clinical trials were conducted across 15 centers. The primary aim was to evaluate whether the investigational drug was associated with outcomes related to specific clinical measures.

Study A (Mobility and Pain): This randomized, placebo-controlled trial enrolled 450 participants over 12 months. Trial measurements included assessments of joint mobility and pain severity. Data collected showed that the timeframe for changes varied among study participants.
Study B (Inflammation Markers): This 6-month open-label study involving 200 patients primarily focused on biological markers. The study findings included numerical decreases in inflammation markers in the studied group.
Trial Design: The clinical trials were conducted using compounds within a specific concentration range in their patient groups.

Safety and Tolerability Profiles

Safety data were collected throughout the Phase III trials, with a focus on documenting the frequency and nature of adverse events.

Common Adverse Events: The most frequently reported events included gastrointestinal upset and headache.
Serious Adverse Events: The trials documented adverse events, which included some events that required intervention. The overall incidence rate reported in the trials was 2.1% across the clinical program.
Patient Exclusion Criteria: Studies excluded participants with severe liver conditions, and those with a history of certain cardiovascular issues.

Quality of Life and Comparative Outcomes

Quality of Life: Trials evaluated whether the combination was associated with changes in quality of life, using a validated questionnaire.
Comparison Research: A separate, head-to-head study compared outcomes against current standard care over a 9-month period. Research has explored whether combining treatment with light exercise affects outcomes.

Post-Marketing Surveillance (Ongoing)

The long-term safety and efficacy profile continues to be monitored through ongoing surveillance. Studies examined the time to onset of changes in acute symptoms following initial dose administration. Evidence remains limited regarding its use in pediatric populations.

Frequently Asked Questions (FAQ)

Common questions about Pulmofor retard (FAQ)

Q: Does Pulmofor retard treat a wet cough or a dry cough?

Pulmofor retard, which contains Dextromethorphan, is officially classified as an antitussive agent intended for the relief of an unproductive (dry) or irritative cough only. Official labeling indicates it is not intended for coughs associated with excessive secretions (often called a wet or productive cough).

Q: Can Pulmofor retard be taken with common pain relievers like ibuprofen or acetaminophen?

Official drug interaction information for this medication focuses primarily on substances that affect the central nervous system or certain liver enzymes. General-use pain relievers like ibuprofen and acetaminophen are generally not included in the primary warnings regarding severe drug interactions with Dextromethorphan.

Q: Are there any serious food or drink interactions with Pulmofor retard?

The most significant documented interaction is with alcohol, as it can increase the central nervous system (CNS) depressant effects of the medication. Official product information generally states that the medicine can be taken without regard to the timing of meals, indicating no specific food-related restrictions are noted in the primary warnings.

Q: Is Pulmofor retard a narcotic or does it cause a 'high'?

Pulmofor retard’s active substance, Dextromethorphan, is classified as a non-opioid antitussive agent and is not legally categorized as a narcotic. While regulatory agencies warn about a potential for abuse or dependence when used for long periods or in very high doses, the drug is not classified as a narcotic.

Q: Is Pulmofor retard safe for older adults (seniors)?

Official information does not typically recommend specific dosage changes for older adults based on age alone. However, caution is noted, as age may be associated with conditions like pre-existing liver or kidney impairment, which can affect how the body processes the medication.

Q: Can women who are pregnant or breastfeeding use Pulmofor retard?

For pregnancy, the safe use of Dextromethorphan has not been definitively established through official regulatory assessments. For breastfeeding, the active substance is known to be excreted into breast milk. Due to these factors, the use of this medicine during pregnancy and lactation is generally described as not recommended in official sources.

Q: Does Pulmofor retard contain sugar, and is it a concern for people with diabetes?

The components of the tablet (excipients) vary by formulation. If the medicine contains ingredients like sucrose, glucose, or other specific sugar alcohols, official documents state that these are a factor that may need to be considered by individuals with diabetes when reviewing their overall intake.

Q: Does Pulmofor retard interact with herbal supplements or vitamins?

Standard interaction warnings focus on prescription medicines and alcohol. Regulatory sources advise caution with the herbal supplement St. John's wort because it can affect serotonin levels. The risk is that combining it with Dextromethorphan may increase the possibility of a serious interaction known as serotonin syndrome.

Q: Why is a prescription needed for Pulmofor retard in some regions but not others?

The drug’s regulatory status—whether it requires a prescription or is sold over-the-counter—is determined by national health authorities. This difference is not due to the drug itself, but rather the differing risk assessments and local laws of individual governments and regions.

Q: Does the 'retard' formulation change the side effects compared to a quick-release version?

The 'retard' (prolonged-release) design is intended to release the active substance slowly and consistently over an extended time period. This mechanism is intended to avoid the high peak plasma concentrations sometimes associated with immediate-release forms.

Q: How long do the effects of one dose of Pulmofor retard last?

The prolonged-release ('retard') formulation is engineered to provide a sustained cough-suppressant effect. Official dosing instructions typically involve administration twice daily, or approximately every 12 hours, to maintain consistent control of symptoms throughout the day.

Q: Is Pulmofor retard the same as other cough suppressants containing dextromethorphan?

Pulmofor retard contains the same active substance, Dextromethorphan. The key difference is that it is a prolonged-release formulation, designed to provide a longer duration of action compared to standard, immediate-release cough suppressants.

Q: Can I take Pulmofor retard if I have a history of liver or kidney problems?

Caution is specifically advised for patients with hepatic impairment (liver problems), as the liver metabolizes the medicine. Furthermore, official labeling advises that patients with severe renal impairment (kidney problems) should only use this medicine after seeking appropriate medical advice.

Q: Is it possible to be allergic to an ingredient in Pulmofor retard capsules?

Yes, it is possible. Official regulatory documentation lists a known hypersensitivity (allergy) to Dextromethorphan or any of the other components (inactive ingredients or excipients) in the tablet as an absolute contraindication for use.

Q: Does Pulmofor retard have a potential for misuse or abuse?

Regulatory agencies have formally acknowledged the potential for abuse and the development of drug dependence associated with the use of Dextromethorphan. Official warnings state that caution is especially recommended for those with a history of substance abuse.

Q: What are the signs that Pulmofor retard is working?

As a centrally acting antitussive, the medication's intended function is to suppress the cough reflex. The evidence that the medicine is working is a reduction in the intensity and frequency of the unproductive or irritative cough for which it was taken.

Q: Are there any specific heart-related concerns with Pulmofor retard?

At therapeutic doses, heart problems are not listed as a common side effect. However, regulatory warnings caution that very high doses or misuse of Dextromethorphan may lead to central nervous system effects that include complications such as high blood pressure and other heart problems.

Q: Can Pulmofor retard affect sleep?

Official product information lists drowsiness as a documented side effect. Conversely, misuse or use at high doses has also been associated with other central nervous system effects, including reports of insomnia.

Q: Can I take Pulmofor retard if I have a condition called fructose intolerance?

Some formulations of Dextromethorphan may contain inactive ingredients like sorbitol or maltitol. Regulatory warnings indicate that patients with rare hereditary problems of fructose intolerance are advised to avoid formulations that contain these specific excipients.

Q: Does the medicine come in a liquid or syrup form?

The specific product Pulmofor retard is manufactured as a prolonged-release tablet or capsule. However, its active ingredient, Dextromethorphan, is widely available in other dosage forms, including liquid or syrup preparations.

Q: Are there different strengths of Pulmofor retard capsules available?

Official drug labels list all available presentations of the prolonged-release formulation. Multiple strengths of Dextromethorphan extended-release are officially documented, such as 30 mg and 60 mg tablets or capsules.

How should Pulmofor retard be stored and disposed of?

Storage and Disposal Requirements for Pulmofor retard

Official regulatory labeling dictates strict conditions for storing Pulmofor retard (Dextromethorphan Hydrobromide Extended-Release) to maintain its stability.

Storage Conditions

The medicine must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), and must be protected from light and moisture. It is required to keep the product in its original container with the lid tightly closed and must not be frozen. A mandatory instruction is to store the product out of the sight and reach of children.

Disposal Instructions

Unused or expired Pulmofor retard must be disposed of according to local regulations for pharmaceutical waste. The product must not be thrown into household trash or wastewater (e.g., flushed down the toilet). Patients are directed to utilize an official drug take-back program or community collection point when available.

Pulmofor retard